Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 6
2005 6
2006 5
2007 4
2008 4
2009 4
2010 4
2011 1
2012 3
2013 8
2014 6
2015 6
2016 4
2017 3
2018 11
2019 3
2020 14
2021 8
2022 9
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Henry DH, Glaspy J, Harrup R, Mittelman M, Zhou A, Carraway HE, Bradley C, Saha G, Modelska K, Bartels P, Leong R, Yu KP. Henry DH, et al. Among authors: mittelman m. Am J Hematol. 2022 Feb 1;97(2):174-184. doi: 10.1002/ajh.26397. Epub 2021 Nov 9. Am J Hematol. 2022. PMID: 34724251 Free article. Clinical Trial.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Cheson BD, et al. Among authors: mittelman m. Blood. 2006 Jul 15;108(2):419-25. doi: 10.1182/blood-2005-10-4149. Epub 2006 Apr 11. Blood. 2006. PMID: 16609072 Free article.
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group. Fenaux P, et al. Among authors: mittelman m. Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13. Blood. 2011. PMID: 21753188 Free article. Clinical Trial.
Erythropoietin: the swinging pendulum.
Oster HS, Neumann D, Hoffman M, Mittelman M. Oster HS, et al. Among authors: mittelman m. Leuk Res. 2012 Aug;36(8):939-44. doi: 10.1016/j.leukres.2012.04.017. Epub 2012 May 11. Leuk Res. 2012. PMID: 22579365 Review.
Gaucher disease, myelodysplastic syndrome and ICUS.
Ruchlemer R, Mittelman M, Zimran A. Ruchlemer R, et al. Among authors: mittelman m. Blood Cells Mol Dis. 2020 Feb;80:102373. doi: 10.1016/j.bcmd.2019.102373. Epub 2019 Oct 18. Blood Cells Mol Dis. 2020. PMID: 31718920
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
114 results